Recombinant Human CEACAM-21 Fc Chimera Protein, CF

When Recombinant Human Galectin-3 (Human Cell-expressed) (Catalog # 8259-GA) is coated at 1 μg/mL, 100 μL/well, Recombinant HumanCEACAM-21 Fc Chimera (Catalog # 9870-CM) binds with an ED50 of0.07-0.7 μg/mL.

2 μg/lane of Recombinant Human CEACAM-21 was resolved with SDS-PAGEunder reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 62 - 72 kDa and 130 - 140 kDa,respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CEACAM-21 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Galectin-3 (Catalog # 8259-GA) is immobilized at 1 μg/mL, 100 μL/well, it binds Recombinant Human CEACAM-21 Fc Chimera. The concentration of Recombinant Human CEACAM-21 Fc Chimera that produces 50% of the optimal binding response is
  0.07-0.7 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human CEACAM-21 protein
  

  Human CEACAM-21 (Trp35-Gly240) Accession # NP_001091976	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: NP_001091976
• N-terminal Sequence: Trp35
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 62-72 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CEACAM-21 Fc Chimera Protein, CF

• carcinoembryonic antigen-related cell adhesion molecule 21
• CEACAM21
• CEACAM-21
• CEACAM3
• FLJ13540
• MGC119874
• R29124_1

Background

Carcinoembryonic antigen-related cell adhesion molecule-21 (CEACAM-21) is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. The CEACAM-21 gene codes for both the CEACAM-3 and CEACAM-21 proteins and is located on chromosome 19. For CEACAM-21, the gene codes a 258 amino acid (aa) polypeptide consisting of a 206 aa extracellular domain (ECD), a 21 aa transmembrane domain, and a 32 aa cytoplasmic domain. The mature ECD contains a single IgV-like domain, common to all members of the CEACAM family, and one IgC2-like domain (1). CEACAM-21 is thought to be a primate-specific gene, and to date, no orthologs have been identified in lower species (2). Originally discovered as a biomarker for colorectal cancer (3), CEACAMs have now been associated with numerous intracellular signaling processes including cell adhesion, cell growth, recognition and differentiation, angiogenesis, and apoptosis (4-6). Although the specific function of the CEACAM-21 protein has yet to be elucidated, CEACAM-21 has been found to be overexpressed in heavy smokers (7) and is associated with COPD susceptibility (8). It is also a candidate gene for schizophrenia in the Jewish population (9). CEACAM family members were identified as the major Galectin-3 receptor candidates on human neutrophils (10). Binding of carbohydrate ligands to CEACAMs may be important in the release of proinflammatory mediators (11, 12).

1. Tchoupa, A. et al. (2014) J Cell Commun Signal 12:27.
2. Zebhauser, R. et al. (2005) Genomics 86:566.
3. Gold, P. and Freedman S.O. (1965) J Exp Med 122:467.
4. Obrink, B. (1997) Curr Opin Cell Biol 9:616.
5. Horst, A.K. Wagener, C. (2004) Handb Exp Pharmacol 283.
6. Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
7. Fukuda, I. et al. (1998) J. Med. Syst. 22:89.
8. Qiu, W. et al. (2011) PLoS ONE 6:e24395.
9. Alkelai, A. et al. (2012) Int. J. Neuropsycopharmacol. 15:459.
10. Feuk-Lagerstedt, E. et al. (1999) J. Immunol. 163:5592.
11. Yoon, J. et al. (2007) J. Immunol. 179:8454.
12. Schröder, A.K. et al. (2006) Hum Immunol. 67:676.

Bioinformatics

• Uniprot:
  • NP_001091976()